Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.91 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 0.89 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.89 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.89 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeine SCHEMBL3047133 | 1.00 | OPRM1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL38654010 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL10747292 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL24865 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL24863 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL24864 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL10747288 | 0.99 | OPRD1 (0.91) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL7936660 | 0.96 | OPRD1 (0.86) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3475282 | 0.96 | OPRD1 (0.89) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL7632902 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164835-A1 | Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations | PISGAH LABORATORIES, INC. | 2015-06-18 | — | — | US | disclosed |
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-1638975-A2 | METHOD FOR PREPARING OXYCODONE | Boehringer Ingelheim Chemicals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-6469170-B1 | PRODUCING A DIENOL ORGANOSILYL ETHER AT POSITION 6 OF THE C-RING OF CODEINONE THEREBY FORMING DIENOL ORGANOSILYL ETHER CONGENER OF CODEINONE; OXIDIZING DIENOL ORGANOSILYL ETHER TO FORM 14-HYDROXYCODEINONE; HYDROGENATING TO PRODUCE OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143183-A1 | METHOD FOR PREPARING OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2002-10-03 | — | — | US | disclosed |
| US-6403798-B2 | PRODUCING A DIENOL ORGANOSILYL ETHER AT POSITION 6 OF THE C-RING OF CODEINONE THEREBY FORMING A DIENOL ORGANOSILYL ETHER CONGENER OF CODEINONE, OXIDIZING THE INTERMEDIATE TO FORM 14-HYDROXYCODEINONE, AND HYDROGENATING UNSATURATION | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6262266-B1 | REACTING MORPHINAN-6-ONE COMPOUND WITH ORGANOSILYL COMPOUND IN PRESENCE OF STRONG AMINE BASE AND APROTIC SOLVENT | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-20010005754-A1 | Method for preparing oxycodone | CHIU FANG-TING (US) | 2001-06-28 | — | — | US | disclosed |
| WO-2001029047-A2 | METHOD FOR PREPARING OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029048-A2 | METHOD FOR PREPARING OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| US-6177567-B1 | FORMATION OF AN DIENOLSILYL ETHER CONGENER OF CODEINONE; OXIDATION OF THE DIENOLSILYL ETHER CONGENER AND HYDROGENATION OF THE RESULTING 14-HYDROXYCODEINONE PRODUCT. | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2001-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | OPRM1 209/4885OPRD1 215/4885OPRK1 72/4885 |
| US-20010005754-A1 | Method for preparing oxycodone | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20150164835-A1 | Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20020143183-A1 | METHOD FOR PREPARING OXYCODONE | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.